<DOC>
	<DOC>NCT02243202</DOC>
	<brief_summary>The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.</brief_summary>
	<brief_title>Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants</brief_title>
	<detailed_description>This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled (an inactive substance that is compared with a medication to test whether the medication has a real effect), parallel-group, multicenter study of the effects of canagliflozin and phentermine co-administration in non-diabetic overweight or obese participants. The study will be conducted for about 33 weeks, approximately 344 participants will be randomly assigned in a 1:1:1:1 ratio to one of the four treatment groups: co-administration of canagliflozin and phentermine, canagliflozin alone, phentermine alone, or placebo. All participants will be also provided with diet and exercise counseling for weight loss (standardized non-pharmacological therapy).</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Must have BMI &gt;=30 kg/m2 and &lt;50 kg/m2 at screening or BMI &gt;=27 kg/m2 and &lt;50 kg/m2 at screening in the presence of a comorbidity of hypertension and/or dyslipidemia Must have stable weight, ie, change of &lt; =5% in the 3 months before screening Must agree to utilize a highly effective method of birth control An established diagnosis of diabetes mellitus Has a history of obesity with a known secondary cause (eg, Cushing's disease/syndrome) Has a history of hereditary glucosegalactose malabsorption or primary renal glycosuria Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 12 weeks before screening Has an Glycated hemoglobin (HBA1c) greater than or equal (&gt;=) to 65 percent An average of 3 seated blood pressure (BP) readings of systolic BP &gt;= 160 mm Hg and/or Diastolic BP &gt;= 100 millimeters of mercury at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Phentermine</keyword>
	<keyword>INVOKANAÂ®</keyword>
</DOC>